Latest Commercial Milestones News

InteliCare Holdings has secured a binding agreement to trial its AI-driven platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy within Victoria’s aged care sector.

Simble Solutions reported a 39% rise in customer cash receipts for Q1 FY25 and strengthened its market position through strategic partnerships and renewable energy initiatives.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.

Sprintex Limited has advanced its commercial and technological milestones with major European and Indian orders, breakthrough energy efficiency validation, and a successful A$3.25 million equity raise, positioning the company for accelerated growth.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

Micro-X Limited has initiated a $2.7 million retail entitlement offer as part of a broader $6 million capital raising, supporting its strategic pivot towards medical imaging technologies and strengthening its balance sheet.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

Micro-X has raised $3.3 million through a placement and institutional entitlement offer, reinforcing its strategic shift towards medical imaging technologies. A retail entitlement offer aiming to raise an additional $2.7 million will open shortly, supporting the company’s development of mobile X-ray and CT products.